These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22792751)

  • 41. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.
    Windisch M; Gschanes A; Hutter-Paier B
    J Neural Transm Suppl; 1998; 53():289-98. PubMed ID: 9700665
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmaceutical treatment of cognitive disorders in Alzheimer's disease.
    Senin U; Cherubini A; Palumbo B; Mecocci P
    Funct Neurol; 1997; 12(3-4):211-2. PubMed ID: 9218980
    [No Abstract]   [Full Text] [Related]  

  • 43. A double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of Cerebrolysin in patients with acute ischaemic stroke in Asia--CASTA.
    Hong Z; Moessler H; Bornstein N; Brainin M; Heiss WD;
    Int J Stroke; 2009 Oct; 4(5):406-12. PubMed ID: 19765131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neuroprotective therapy.
    Grotta JC; Hickenbottom S
    Rev Neurol (Paris); 1999; 155(9):644-6. PubMed ID: 10528342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease.
    Ahlemeyer B; Krieglstein J
    Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S8-14. PubMed ID: 13130383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is it time to definitely abandon neuroprotection in acute ischemic stroke?
    Sacchetti ML
    Stroke; 2008 Jun; 39(6):1659-60. PubMed ID: 18369169
    [No Abstract]   [Full Text] [Related]  

  • 47. [Monitoring of neurotrophic factors and cognitive function in patients with traumatic brain injury].
    Karakulova YV; Selyanina NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):34-37. PubMed ID: 29171486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Cerebrolysin on neurogenesis in an APP transgenic model of Alzheimer's disease.
    Rockenstein E; Mante M; Adame A; Crews L; Moessler H; Masliah E
    Acta Neuropathol; 2007 Mar; 113(3):265-75. PubMed ID: 17131129
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rivastigmine for Alzheimer's disease.
    Desai AK; Grossberg GT
    Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A comparison of a neuroprotective effects of hypoxic postconditioning and cerebrolysin in the experimental model].
    Rybnikova EA; Vorob'ev MG; Pivina SG; Samoĭlov MO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2):54-8. PubMed ID: 23528584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioral and cognitive disturbances in endogenous childhood autism].
    Radzivil MG; Bashina VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(2):21-5. PubMed ID: 16548370
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A progressive view on the treatment and rehabilitation of acute ischemic stroke].
    Yanishevskiy SN; Khatkova SE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(12. Vyp. 2):50-54. PubMed ID: 36582161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research.
    Ye M; Fu S; Pi R; He F
    J Pharm Pharmacol; 2009 Jul; 61(7):831-7. PubMed ID: 19589224
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Tanakan as a multimodal cytoprotective factor in general medicine].
    Naprienko MV; Esin RG; Mukhametova ER; Esin OR; Smekalkina LV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):146-151. PubMed ID: 27030838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. More than a decade of estrogen neuroprotection.
    Simpkins JW; Singh M
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S131-6. PubMed ID: 18631989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.
    Choi Y; Kim HS; Shin KY; Kim EM; Kim M; Kim HS; Park CH; Jeong YH; Yoo J; Lee JP; Chang KA; Kim S; Suh YH
    Neuropsychopharmacology; 2007 Nov; 32(11):2393-404. PubMed ID: 17406652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial effect of cerebrolysin on moderate and severe head injury patients: result of a cohort study.
    Wong GK; Zhu XL; Poon WS
    Acta Neurochir Suppl; 2005; 95():59-60. PubMed ID: 16463821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cerebrolysin attenuates blood-brain barrier and brain pathology following whole body hyperthermia in the rat.
    Sharma HS; Zimmermann-Meinzingen S; Sharma A; Johanson CE
    Acta Neurochir Suppl; 2010; 106():321-5. PubMed ID: 19812972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroprotective effects of salvianolic acid B on an Aβ25-35 peptide-induced mouse model of Alzheimer's disease.
    Lee YW; Kim DH; Jeon SJ; Park SJ; Kim JM; Jung JM; Lee HE; Bae SG; Oh HK; Son KH; Ryu JH
    Eur J Pharmacol; 2013 Mar; 704(1-3):70-7. PubMed ID: 23461850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.